Head to Head Review: Lucid Diagnostics (NASDAQ:LUCD) vs. Pressure BioSciences (OTCMKTS:PBIO)

Lucid Diagnostics (NASDAQ:LUCD) and Pressure BioSciences (OTCMKTS:PBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Volatility & Risk

Lucid Diagnostics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Pressure BioSciences has a beta of -0.8, suggesting that its share price is 180% less volatile than the S&P 500.

Profitability

This table compares Lucid Diagnostics and Pressure BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,426.27%	N/A	-95.51%
Pressure BioSciences	N/A	N/A	N/A

Valuation & Earnings

This table compares Lucid Diagnostics and Pressure BioSciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71 million	46.96	-$58.01 million	($0.96)	-1.30
Pressure BioSciences	$1.98 million	0.03	-$29.31 million	($0.96)	0.00

Pressure BioSciences has lower revenue, but higher earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Lucid Diagnostics and Pressure BioSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Pressure BioSciences	0	0	0	0	0.00

Lucid Diagnostics presently has a consensus price target of $4.13, suggesting a potential upside of 230.00%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, research analysts clearly believe Lucid Diagnostics is more favorable than Pressure BioSciences.

Insider and Institutional Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 0.0% of Pressure BioSciences shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 10.8% of Pressure BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Lucid Diagnostics beats Pressure BioSciences on 7 of the 12 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.